Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Portfolio Pulse from
Barinthus Bio announced positive results from its ongoing Phase 2b trial for chronic Hepatitis B, with eight participants achieving HBsAg loss and two meeting criteria for a functional cure.
November 15, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barinthus Bio's Phase 2b trial for chronic Hepatitis B showed promising results, with eight participants achieving HBsAg loss and two achieving a functional cure. This could positively impact the company's stock price.
The achievement of a functional cure in two participants and HBsAg loss in eight participants is a significant milestone in the trial, indicating potential success in treating chronic Hepatitis B. This positive development is likely to boost investor confidence and positively impact the stock price of Barinthus Bio.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100